A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Ipatasertib (Primary) ; Docetaxel; Enzalutamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 29 Jun 2018 Planned End Date changed from 29 Jun 2018 to 30 Jun 2019.
- 29 Jun 2018 Planned primary completion date changed from 29 Jun 2018 to 30 Jun 2019.
- 21 Nov 2017 Planned End Date changed from 31 Oct 2017 to 29 Jun 2018.